bi 767551
mAbexperimentalCOVID-19
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
2
Phase 4
0
Earliest trial started Apr 21, 2021 (NCT04822701)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Spike glycoproteinANTAGONIST
Spike glycoprotein antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04894474 | Phase 2/Phase 3 (Phase 3) | Jun 17, 2021 | Boehringer Ingelheim |
| NCT04822701 | Phase 2/Phase 3 (Phase 3) | Apr 21, 2021 | Boehringer Ingelheim |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 2 | 2 | 1 | 2021 |
1 organizations
Page 1 / 1